Reducing treatment burden in the era of CFTR modulators

Abstract

Competing Interests: PDR's institutions have received reimbursement for services provided as part of a central over-reading centre network for multiple breath washout in both investigator and pharmaceutical sponsored studies (including Vertex Pharmaceuticals). TAD's institution has received payment on a per-patient basis derived from pharmaceutical studies, honoraria for symposia, and educational meetings from Vertex Pharmaceuticals. CEW's institution has received payment for consultancy work on a per-patient basis derived from pharmaceutical studies sponsored by GSK, Boehringer Ingelheim, and Vertex Pharmaceuticals; a research grant from Novo Nordisk; honoraria for participation in advisory boards, symposia, and meetings from DKBmed, Novartis Pharmaceuticals, University of Miami, and Vertex Pharmaceuticals; travel support from Vertex Pharmaceuticals; and serves on the International Advisory Board for Vertex Pharmaceuticals.